Industry Insights

  1. BIO 2016 Survey: Where Is Biopharma Headed?

    15,937 industry leaders, 40% of which were C-level executives, attended the BIO International Convention in San Francisco that ran June 6-9. The MilliporeSigma team used this opportune gathering of the biopharma industry to unveil the findings of a study that it recently sponsored with The Economist Intelligence Unit, titled The Changing Biopharma Risk Equation.

  2. Key Considerations When Sourcing Reference Products For Biosimilar Studies

    In order to ensure a smooth development and clinical process, companies must carefully plan their activities with regard to the innovator biopharmaceutical. 

  3. Single-Use Adoption Drives Need For Range Of Sterile Connector Technologies

    The adoption of disposable bioprocessing equipment has already been widespread for small-scale applications at the development and clinical manufacturing stages.

  4. Can The Cloud Prevent Collaboration Failure In Biopharma?

    Working in a cloud-based information management and collaboration workspace provides a level of business agility and security that is not available with server-based, on-premises infrastructure.

  5. Importance Of Information Sharing In Pharmaceutical Cold Chains

    To ensure quality of pharmaceutical raw materials and products, it is very important to monitor specific factors throughout supply chain. In cold chains, temperature is closely controlled and monitored.

  6. An Efficient Purification Platform For Recombinant Proteins

    Mixed-mode chromatography matrices are designed to present multiple interaction modes to resolve target proteins and impurities, entities that are themselves complex multimodal molecules. 

  7. Single-Use Technology: The Next 5 Challenges to Conquer

    While single-use processing has limitations with scale of operations when compared to stainless steel setups, several trends are mitigating the impact of these limitations significantly.

  8. Advantages of Multidimensional (Multi-D) Chromatography —What’s it all about

    The need for companies to shorten their development or manufacturing time means that process development must be fast and inexpensive without compromising the quality of the end product. To address this challenge, many companies are moving towards automation.

  9. Sanofi Asks — Will Standardization Take End User & Supplier Relationships To The Next Level?

    A larger scale adoption of SUT may continue to be delayed as biopharmaceutical manufacturers must have access to a reliable supply chain that allows us to successfully deliver product to our customers.

  10. Factors To Consider When Selecting A Pharmaceutical Contract Manufacturer (CMO)

    Key drivers to help you make the right decision if you do turn to a pharmaceutical CMO.